OXS-1550 is a bi-specific antibody drug conjugate (ADC) that is currently in a Phase I/II trial for B-cell leukemias and lymphomas. The ADC targets CD19 and CD22 on B-lymphocytes and has a cytotoxic drug payload of diphtheria toxin (DT390) attached. CD19 is a protein expressed on all B lineage cells and is a biomarker for B-lymphocyte development and lymphoma diagnosis. It can also be used as a biomarker on leukemia immunotherapies. CD22 is another protein found on the surface of B cells and is a regulatory molecule that prevents the overactivation of the immune system and development of autoimmune diseases.
The attractiveness of the platform is its flexibility to target other tumor antigens and carry a variety of payloads for delivery to the cell.
Market Data 
Markets 
AI
